Abstract
Gonorrhea is the second most common communicable disease in the United States. From 2010 to 2014, the rate of this sexually transmitted disease increased by 10.5% in the U.S. Cefixime, which was once the first-line agent for the treatment of Neisseria gonorrhoeae, is rapidly waning in efficacy, as are several other cephalosporins. Similarly, fluoroquinolone-resistant strains of N gonorrhoeae have been reported. As a result, the use of these agents has decreased. The CDC currently recommends dual treatment with ceftriaxone and azithromycin for most gonococcal infections. Multidrug-resistant gonorrhea is becoming a serious health threat in the U.S.
Original language | English (US) |
---|---|
Pages | 41-44 |
Number of pages | 4 |
Volume | 41 |
No | 8 |
Specialist publication | U.S. Pharmacist |
State | Published - Aug 1 2016 |
All Science Journal Classification (ASJC) codes
- Pharmacy
- Pharmacology
- Pharmaceutical Science